Evidence map›Paper›PMID 38117000›Full record

ArticleJournal of extracellular vesicles2023

Extracellular vesicles derived from nasopharyngeal carcinoma induce the emergence of mature regulatory dendritic cells using a galectin-9 dependent mechanism.

Anthony Lefebvre, Camille Trioën, Sarah Renaud, William Laine, Benjamin Hennart, Clément Bouchez, Bertrand Leroux, Delphine Allorge, Jérôme Kluza, Elisabeth Werkmeister and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Anthony LefebvreUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.
Camille TrioënUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.
Sarah RenaudUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.
William LaineUniv. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
Benjamin HennartCHU Lille, Laboratoire de Toxicologie, Lille, France.
Clément BouchezUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.
Bertrand LerouxUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.
Delphine AllorgeCHU Lille, Laboratoire de Toxicologie, Lille, France.
Jérôme KluzaUniv. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
Elisabeth WerkmeisterUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.
Guillaume Paul GrolezUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.
Nadira DelhemUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.
Olivier MoralèsUniv. Lille, Inserm, CHU Lille U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, Lille, France.ORCID 0000-0002-2135-3265
Inserm · FRCentre National de la Recherche Scientifique · FRUniversité de Lille · FR

Funding

Canceropole Nord Ouest CNO2014Canceropole Nord Ouest CNO2019
6 · The paper itself

Abstract

Nasopharyngeal carcinoma-derived small extracellular vesicles (NPCSEVs) have an immunosuppressive impact on the tumour microenvironment. In this study, we investigated their influence on the generation of tolerogenic dendritic cells and the potential involvement of the galectin-9 (Gal9) they carry in this process. We analysed the phenotype and immunosuppressive properties of NPCSEVs and explored the ability of DCs exposed to NPCSEVs (NPCSEV-DCs) to regulate T cell proliferation. To assess their impact at the pathophysiological level, we performed real-time fluorescent chemoattraction assays. Finally, we analysed phenotype and immunosuppressive functions of NPCSEV-DCs using a proprietary anti-Gal9 neutralising antibody to assess the role of Gal9 in this effect. We described that NPCSEV-DCs were able to inhibit T cell proliferation despite their mature phenotype. These mature regulatory DCs (mregDCs) have a specific oxidative metabolism and secrete high levels of IL-4. Chemoattraction assays revealed that NPCSEVs could preferentially recruit NPCSEV-DCs. Finally, and very interestingly, the reduction of the immunosuppressive function of NPCSEV-DCs using an anti-Gal9 antibody clearly suggested an important role for vesicular Gal9 in the induction of mregDCs. These results revealed for the first time that NPCSEVs promote the emergence of mregDCs using a galectin-9 dependent mechanism and open new perspectives for antitumour immunotherapy targeting NPCSEVs.

Indexed as

Extracellular VesiclesNasopharyngeal NeoplasmsDendritic CellsGalectinsHumansNasopharyngeal CarcinomaTumor MicroenvironmentGalectinsextracellular vesiclesgalectin-9IDOIL-4IL4I1mature regulatory dendritic cellsmetabolismnasopharyngeal carcinoma

Identifiers

PMID38117000
PMCPMC10731827
OpenAlexW4389996562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.